TNF and infection: Similarly, the American College of Rheumatology (ACR) guidelines for RA recommend early and aggressive treatment with biologics such as TNF inhibitors, IL-6 inhibitors, and JAK inhibitors, particularly for patients with high disease activity, while emphasizing the need to weigh the benefits against risks like serious infections and malignancies [5].